Anacetrapib in familial hypercholesterolaemia: Pros and cons

The Lancet

Volumn 385, Issue 9983, 2015, Pages 2124-2126

  Raal, Frederick J ^a   Blom, Dirk J ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; EVACETRAPIB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; HYPOCHOLESTEROLEMIC AGENT; OXAZOLIDINONE DERIVATIVE;

ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DRUG MEGADOSE; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; LOSS OF FUNCTION MUTATION; MENDELIAN RANDOMIZATION ANALYSIS; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); FEMALE; HYPERLIPOPROTEINEMIA TYPE II; MALE;

ANTICHOLESTEREMIC AGENTS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; OXAZOLIDINONES;

EID: 84930083205     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62315-1     Document Type: Note

References (13)

1. JJP Kastelein, J Besseling, S Shah et al. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study Lancet 2015 published online March 3. http://dx.doi.org/10.1016/S0140-6736(14)62115-2
2. D Keene, C Price, MJ Shun-Shin, DP Francis Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients BMJ 349 2014 g4379
3. BF Voight, GM Peloso, M Orho-Melander et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study Lancet 380 2012 572 580
4. A Rohatgi, A Khera, JD Berry et al. HDL cholesterol efflux capacity and incident cardiovascular events N Engl J Med 371 2014 2383 2393
5. TH Johannsen, R Frikke-Schmidt, J Schoou, BG Nordestgaard, A Tybjærg-Hansen Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects J Am Coll Cardiol 60 2012 2041 2048
6. PJ Barter, M Caulfield, M Eriksson for the ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
7. GG Schwartz, AG Olsson, M Abt for the dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
8. HH Schmidt, S Hill, EV Makariou, IM Feuerstein, KA Dugi, JM Hoeg Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia Am J Cardiol 77 1996 575 580
9. J Versmissen, DM Oosterveer, M Yazdanpanah et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study BMJ 337 2008 a2423
10. FJ Raal, GJ Pilcher, VR Panz et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy Circulation 124 2011 2202 2207
11. CP Cannon IMPROVE-IT trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes 2014 American Heart Association Scientific Sessions Chicago, USA Nov 15-19, 2014.
12. F Raal, R Scott, R Somaratne et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2417
13. JC Cohen, E Boerwinkle, TH Mosley Jr, HH Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272